Drugs / IBI3009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06613009 | Dec 2024 → Aug 2027 expected | small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06613009 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection” NCT06613009 ↗ |